Obesity Promotes Liver Carcinogenesis via Mcl-1 Stabilization Independent of IL-6Rα Signaling  by Gruber, Sabine et al.
Cell Reports
ReportObesity Promotes Liver Carcinogenesis
via Mcl-1 Stabilization
Independent of IL-6Ra Signaling
Sabine Gruber,1 Beate K. Straub,2 P. Justus Ackermann,1 Claudia M. Wunderlich,1 Jan Mauer,1 Jens M. Seeger,3
Hildegard Bu¨ning,4 Lukas Heukamp,5 Hamid Kashkar,3 Peter Schirmacher,2 Jens C. Bru¨ning,1
and F. Thomas Wunderlich1,*
1MaxPlanck Institute for Neurological ResearchCologne; Institute for Genetics, University of Cologne; Cologne ExcellenceCluster onCellular
Stress Responses in Aging-associated Diseases (CECAD); Center for Molecular Medicine Cologne (CMMC); Center for Endocrinology,
Diabetes and Preventive Medicine (CEDP) Cologne, 50931 Cologne, Germany
2Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany
3Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne; CMMC; CECAD; 50937 Cologne, Germany
4Department I of Internal Medicine, University of Cologne; CMMC; 50935 Cologne, Germany
5Institute of Pathology, University of Cologne, 50937 Cologne, Germany
*Correspondence: thomas.wunderlich@uni-koeln.de
http://dx.doi.org/10.1016/j.celrep.2013.07.023
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works
License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are
credited.SUMMARY
Obesity increases the incidence of hepatocellular
carcinoma (HCC) development in part through the
activation of obesity-associated proinflammatory
signaling. Here, we show that in lean mice, abroga-
tion of IL-6Ra signaling protects against diethylni-
trosamine (DEN)-induced HCC development. HCC
protection occurs via Mcl-1 destabilization, thus pro-
moting hepatocyte apoptosis. IL-6 regulates Mcl-1
stability via the inhibition of PP-1a expression, pro-
moting GSK-3b inactivation. In addition, IL-6 sup-
presses expression of the Mcl-1 E3 ligase (Mule).
Consequently, IL-6Ra deficiency activates PP-1a
and Mule expression, resulting in increased Mcl-1
turnover and protection against HCC development.
In contrast, in obesity, inhibition of PP-1a and
Mule expression, leading to Mcl-1 stabilization,
occurs independently of IL-6 signaling. Collectively,
this study provides evidence that obesity inhibits
hepatocyte apoptosis through Mcl-1 stabilization
independent of IL-6 signaling, thus promoting liver
carcinogenesis.
INTRODUCTION
Epidemiological studies have identified obesity as a major risk
factor for several cancer entities (Bianchini et al., 2002; Calle
and Kaaks, 2004), among which hepatocellular carcinoma
(HCC) exhibited the strongest obesity-associated increase in
tumor incidence (Calle et al., 2003). Thus, the obesity-associated
increase in HCC development may gain substantial clinical sig-
nificance in light of the steadily increasing incidence of obesityin westernized societies (Ford and Mokdad, 2008). Obesity is
known to result in a chronic low-grade proinflammatory state
as a consequence of immune cells infiltrating white adipose tis-
sue (WAT) and liver. This in turn results in elevated circulating
concentrations of cytokines such as tumor necrosis factor alpha
(TNF-a) and interleukin-6 (IL-6) (Nishimura et al., 2009; Xu et al.,
2003; Hotamisligil, 2006). Therefore, obesity-associated inflam-
mation provides a potential link between obesity and liver carci-
nogenesis. Accordingly, studying TNF-a- and IL-6-evoked
signaling pathways that are upregulated both in obesity and
during HCC development has provided new insights into the
pathogenesis of these disorders (Park et al., 2010). Impairment
of TNF-a-induced NF-kB signaling in liver parenchymal cells
through liver-specific NEMO deficiency in NEMOL-KO mice
causes spontaneous liver tumorigenesis (Luedde et al., 2007)
that is further aggravated when these animals are exposed to
high fat diet (HFD)-induced obesity (Wunderlich et al., 2008).
Further detailed analyses showed that obese NEMOL-KO mice
sequentially developed liver inflammation with a concomitant in-
crease of IL-6, which eventually contributes to the development
of liver tumors. Importantly, both genetically and diet-induced
obesity are known to aggravate liver carcinogenesis in the
DEN-induced HCC model, and obesity-induced enhancement
of liver carcinogenesis is dependent on TNF-a signal transduc-
tion (Park et al., 2010). In addition, this study also showed that
liver carcinogenesis in lean and obese mice is IL-6 dependent
(Park et al., 2010). Taken together, these findings provide strong
evidence that obesity increases HCC incidence by inducing in-
flammatory conditions that involve TNF-a and IL-6. Moreover,
previous studies have also shown that obesity decreases hepa-
tocyte death (Park et al., 2010). However, the exact underlying
molecular mechanisms and their contribution in both IL-6- and
obesity-induced HCC development still remain to be elucidated.
Here, we show that interleukin-6 receptor a (IL-6Ra) deficiency
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finding that is consistent with the previously described IL-6
dependency of liver tumor development (Naugler et al., 2007).
Moreover, in line with previous observations, HFD-induced
obesity aggravates DEN-induced HCC development and pro-
gression compared to normal chow diet (NCD)-fed mice (Park
et al., 2010). Surprisingly, this HFD-induced obesity abrogates
the protective effect of IL-6Ra deficiency on HCC development.
We show that IL-6 and obesity promote HCC progression
through stabilization of the Bcl-2 family member Mcl-1 that in
turn inhibits apoptosis of damaged hepatocytes and contributes
to malignant transformation and HCC progression. Mcl-1 stabi-
lization in lean mice was found to occur as a consequence of
IL-6-induced glycogen synthase kinase 3 b (GSK-3b) inactivation
as well as reduced Mule expression, whereas in obese animals
this mechanism occurred independently of IL-6 signaling.
Thus, this study has strong implications for current translational
research on HCC therapeutic strategies aiming at reactivating
the mitochondrial apoptotic pathway under inflammatory and
obese conditions.
RESULTS
Obesity Increases Basal Hepatic Stat-3 Activation and
Impairs Acute IL-6 Responsiveness
IL-6 initiates downstream signaling by binding to the IL-6R con-
sisting of two subunits of the signal-transducing b chain of the re-
ceptor that is also used by a cohort of other IL-6-type cytokines
and one subunit of the IL-6Ra chain that confers IL-6 binding and
thus specificity to the receptor complex (Heinrich et al., 2003). IL-
6R activation results in multiple downstream signaling events in
the liver such as activation of the JAK/Stat-3 and MAPK/ERK
pathways, whereas phosphorylation of Stat-3 appeared already
30 min after IL-6 injection and progressively declined thereafter
(Figure S1A). However, IL-6 injection did not activate hepatic
JNK phosphorylation in our control mice (Figure S1A). Next, in
a dose response of IL-6 in lean control mice, IL-6-induced
Stat-3 activation in liver was already detected upon injection of
3 ng IL-6 per gram body weight (BW), which was dose-depen-
dently increased when 30 and 300 ng IL-6/g BW were applied
(Figure S1B). Surprisingly, while injection of 50 ng IL-6/g BW
induced a prominent hepatic activation of Stat-3 in lean mice,
this response was dramatically blunted when control mice
were obese owing to the exposure to HFD (Figures S1C and
S1D). Noteworthy, in the basal state, obese livers demonstrated
increased Stat-3 activation compared to lean mice (Figure S1C).
Collectively, these experiments demonstrate that obesity
increases basal Stat-3 activation and impairs acute respon-
siveness to IL-6, presumably as a result of the low-grade proin-
flammatory state under obese conditions.
To study the role of IL-6Ra-dependent signaling in obesity-
associated liver carcinogenesis, we crossed IL-6RaFL mice
(Wunderlich et al., 2010) to deleter Cre mice and intercrossed
offspring to yield IL-6RaKO mice (Wunderlich et al., 2012). Quan-
titative PCR (qPCR) of liver complementary DNA (cDNA) of
IL-6RaFL control and IL-6RaKO mice revealed the absence of
IL-6Ra expression in IL-6RaKO mice (Figure S1E). Accordingly,
IL-6 was unable to induce hepatic Stat-3 phosphorylation in
IL-6RaKO mice, whereas CNTF potently induced Stat-3 activa-670 Cell Reports 4, 669–680, August 29, 2013 ª2013 The Authorstion in these animals (Figure S1F). In contrast, hepatic Stat-3
activation occurred to a similar extent in both control and IL-6-
deficient mice when exposed to IL-6 or CNTF (Figure S1F). In
addition, LPS was observed to potently induce Stat-3 and JNK
phosphorylation in control mice but failed to activate Stat-3 in
IL-6Ra- and IL-6-deficient mice, thereby indicating that LPS-
induced Stat-3 activation is mainly derived from IL-6/IL-6Ra
signaling (Figure S1F). Thus, our experiments revealed success-
ful inactivation of IL-6-evoked signaling in IL-6RaKO mice while
the responsiveness to alternative IL-6Ra-independent gp130 cy-
tokines such as CNTF remained unaltered.
HFD Causes Obesity in Control and IL-6RaKO Mice in the
DEN-Induced HCC Model
HCC represents a classical inflammation-induced cancer entity,
the development of which is significantly enhanced under obese
conditions (Park et al., 2010; Wunderlich et al., 2008). To inves-
tigate whether IL-6Ra deficiency affects HCC development
under normal and obese conditions, we injected male IL-6RaFL
control and IL-6RaKO mice with DEN at 15 days of age and sepa-
rated these animals after weaning in cohorts fed on either an
NCD or HFD. Importantly, HFD significantly increased body
weight (Figure S2A), impaired glucose tolerance (Figure S2B),
and increased circulating concentrations of insulin, TNF-a, and
IL-6 in sera of control and IL-6RaKO mice (Figure S2C–S2E).
However, IL-6Ra deficiency did not affect HFD-induced obesity
or obesity-induced insulin resistance and inflammation. Alterna-
tive modulation of IL-6 type cytokine signaling by trans-signaling
of soluble receptors such as sIL-6Ra and sgp130 might also
contribute to obesity-induced inflammation. However, while
consistently in IL-6Ra-deficient mice the sIL-6Ra was at the
lowest detection level but unchanged between control mice on
both diets, sgp130 was reduced in obese IL-6RaKO mice
compared to lean but comparable to control animals (Figures
S2F and S2G). HFD feeding was observed to induce hepatocyte
steatosis that can sequentially lead to the development of liver
damage and steatohepatitis that in turn might result in HCC
development. As an indirect indicator of liver damage, the activ-
ity of the liver aspartate transaminase AST was not significantly
different in the serum of control and IL-6RaKO mice fed on either
an NCDor HFD (Figure S2H). Oil redO staining of liver sections of
the four different groups of mice revealed increased hepatic fat
stores in mice exposed to HFD feeding in both control and IL-
6RaKO mice, although lipid accumulation was comparable
between the two genotypes (Figure S2I). Taken together, our
data demonstrate that HFD exposure causes similar levels of
obesity in both control and IL-6RaKO mice upon DEN induction.
Obesity Promotes HCC Development and Abrogates the
Effect of IL-6Ra Deficiency on liver Carcinogenesis
We next analyzed tumor development in 8-month-old DEN-
treated control and IL-6RaKO mice that had been exposed to
either an NCD or HFD (Figure 1A). Male control NCD-fed
mice developed approximately 30 macroscopically visible liver
tumors (Figure 1B), of which 66% were smaller than 2 mm (Fig-
ure 1C) and 33% reached a size of more than 2 mm (Figure 1D).
Similar to IL-6-deficient mice (Naugler et al., 2007), we found that
IL-6Ra deficiency potently protected mice from developing
Figure 1. Obesity Compensates for IL-6Ra Deficiency in HCC Pathogenesis
(A) Livers of 8-month-old (8-mo) control and IL-6RaKO mice injected with 25 mg/kg DEN at 15 days of age.
(B) Quantitation of macroscopic tumor multiplicity determined by visual inspection in DEN-injected 8-month-old control and IL-6RaKO mice (n = 15).
(C andD) Enumeration of tumor number for < 2mm (C) and >2mm (D) as determined by visual inspection of DEN-injected 8-mocontrol and IL-6RaKOmice (n = 15).
(E) Hematoxylin/eosin-stained sections of livers from DEN-injected 8-mo control and IL-6RaKO mice. Asterisks indicate tumor foci; arrows indicate tumorous
blood vessel infiltrates.
(F) Quantitation of tumor number per two lobules counted on liver sections from 8-mo control and IL-6RaKO mice (n = 15).
(G) Quantitation of tumor size measured in the big liver lobe of DEN-injected 8-mo control and IL-6RaKO mice (n = 15).
(H) Quantitation of inflammation measured in the big liver lobe of DEN-injected 8-mo control and IL-6RaKO mice. 1 = mild inflammation (mild portal inflammation,
three to five single cell necrosis, no grouped necrosis); 2 = moderate inflammation (moderate portal inflammation, six to nine single cell necrosis, one grouped
necrosis); 3 = severe inflammation (severe portal inflammation, more than ten single cell necrosis, more than one grouped necrosis) (n = 15).
Displayed values are means ± SEM; *p% 0.05, **p% 0.01, ***p% 0.001 versus control. See also Figure S1.DEN-induced HCC when fed on an NCD (Figures 1A–1D). In line
with previous experiments, obesity increased tumor burden to
approximately 50 tumors in control mice (Figures 1A and 1B)(Park et al., 2010). Strikingly, however, when IL-6RaKO mice
were fed a HFD, the protective effect of IL-6Ra deficiency on
HCC development was abrogated as DEN treatment inducedCell Reports 4, 669–680, August 29, 2013 ª2013 The Authors 671
Figure 2. Obesity and IL-6 Accelerate HCC Pathogenesis through Mcl-1 Stabilization
(A) Determination of caspase-3 activity using an ELISA-based assay on liver lysates from DEN-injected 8-mo control and IL-6RaKO mice (n = 5).
(B) Western blot analysis using cleaved caspase-3 and AKT antibodies on liver tissue from 8-week-old (8-wk) control and IL-6RaKO mice fed on an NCD and
sacrificed at the indicated time points after a 100 mg/kg DEN injection.
(legend continued on next page)
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significantly higher tumor numbers in these mice comparable to
control mice with an HFD (Figures 1A and 1B). Histological inves-
tigation of hematoxylin and eosin-stained liver sections (Fig-
ure 1E) confirmed that NCD-fed IL-6RaKO mice had significantly
decreased number and size of HCC foci (Figures 1F and 1G)
when compared to NCD-fed control mice, although this
difference was not as large as observed upon macroscopic
inspection. Strikingly, HFD feeding restored the carcinogenic
capability of DEN in IL-6RaKO animals as the number and size
of HCC foci increased to the same extent in control mice and
IL-6RaKO mice when exposed to an HFD (Figures 1F and 1G).
Moreover, the extent of inflammation as assessed by quantita-
tion of infiltrating immune cells and necrosis of hepatocytes
was significantly reduced in livers of IL-6RaKO mice compared
to control mice exposed to an NCD (Figure 1H). In contrast,
HFD feeding significantly increased liver inflammation of both
control and IL-6RaKO animals (Figure 1H). While it is certainly
not clear which factor in obesity compensates for IL-6Ra
deficiency in HCC development, evidently another IL-6-type
cytokine or receptor might account for this observation, as
inactivation of gp130 in hepatocytes protected against DEN-
induced HCC development even under obese conditions (Fig-
ure S2J). However, determination of IL-6-type cytokine and
receptor expression levels in tumor livers of control and IL-
6Ra-deficient animals under both dietary conditions failed to
directly clarify this point, which needs further investigation (Fig-
ures S2K–S2N). Taken together, these data demonstrate that
obesity promotes HCC development and progression and ren-
ders tumor development independently of IL-6Ra signaling,
thus abrogating the protective function of IL-6Ra deficiency
under NCD conditions.
Obesity and IL-6 Increase HCC Development through
the Inhibition of Mitochondrial Apoptosis
IL-6 is a potent survival signal in hepatocytes, and deletion of its
receptor may thus affect hepatocyte death signaling and sur-
vival. Therefore, we examined apoptosis in the livers of the
different cohorts of mice by determining the presence of active
caspase-3. Increased caspase-3 activation was detected in liver
lysates derived from NCD-fed IL-6RaKO mice upon DEN treat-
ment, whereas significantly decreased caspase 3 activation
was detected in HFD-fed IL-6RaKO mice (Figure 2A). In line
with this observation, upon a single DEN injection, caspase-3
cleavage/activation dramatically increased in livers of IL-6RaKO
mice (Figure 2B). These data were further substantiated by the(C) Determination of serumAST activity to assess liver damage in 8-wk control and
100 mg/kg DEN injection (n = 6).
(D) Cytochrome c release of isolated mitochondria after treatment with increasin
8-wk control and IL-6RaKO mice fed an NCD.
(E) Western blot analysis using cytochrome c and actin antibodies of cytosolic ex
that were treated with 0, 0.25, 0.5, 1, and 5 mM DEN for 48 hr in culture.
(F) Quantitation of proliferating Ki67-positive hepatocytes in liver sections from
injection of 100 mg/kg DEN (n = 3).
(G) Western blot analysis using Mcl-1, Bcl-2, Bcl-XL, and Complex II antibodies
(H) Representative Mcl-1-stained sections of livers from DEN-injected 8-mo contr
(I) Quantitation of Mcl-1 in tumors of the big liver lobe from DEN-injected 8-mo c
(J) Western blot analysis using Mcl-1 and Calnexin antibodies on isolated tumor
Displayed values are means ± SEM; *p% 0.05, **p% 0.01, ***p% 0.001 versusfinding that AST activity was elevated in sera of IL-6RaKO mice
upon acute DEN injection, another strong indicator of liver
damage (Figure 2C). Mitochondria represent a central sensory
organelle that can respond to DNA damage by mitochondrial
outer membrane permeabilization, a process that is tightly regu-
lated by Bcl-2 protein family members (Brunelle and Letai, 2009).
To experimentally address whether increased DEN-induced
apoptosis in IL-6RaKO mice is a consequence of enhancedmito-
chondrial apoptotic response, freshly isolated mitochondria
from livers of naive control and IL-6RaKO mice were incubated
with increasing amounts of recombinant Bax protein and the
release of mitochondrial cytochrome c was measured by west-
ern blot analysis (Figure 2D). These analyses demonstrated
that mitochondria derived from the livers of IL-6RaKO mice
were more susceptible to recombinant Bax as demonstrated
by the increased appearance of cytosolic cytochrome c (Fig-
ure 2D). Consistently, IL-6Ra-deficient hepatocytes demon-
strated concentration-dependent cytosolic cytochrome c levels
in response to DEN (Figure 2E). Collectively, these experiments
demonstrate increased hepatic apoptosis sensitivity of lean IL-
6Ra-deficient mice. Hepatocyte apoptosis has been shown to
result in compensatory proliferation of adjacent hepatocytes to
cause HCC development (Bisgaard and Thorgeirsson, 1996).
Thus, we compared proliferation of hepatocytes in response to
DEN-induced apoptosis in lean control and IL-6RaKO mice (Fig-
ure 2F). While hepatocyte proliferation was significantly reduced
in IL-6Ra-deficient animals without DEN injection, DEN-induced
compensatory proliferation of hepatocytes was comparable
between control and IL-6RaKO mice as examined through quan-
titation of Ki67-positive hepatocytes in livers of these mice.
Thus, increased apoptosis sensitivity, but not impairments in
compensatory proliferation, might confer the protection of lean
IL-6Ra-deficient mice against DEN-induced HCC development.
The balance between anti- and proapoptotic members of the
Bcl-2 protein family regulates mitochondrial outer membrane
permeabilization and the efflux of cytochrome c in response to
cellular damage (Brunelle and Letai, 2009). The presence of the
antiapoptotic Bcl-2 protein family members Mcl-1, Bcl-2, and
Bcl-XL at mitochondria has been shown to prevent cytochrome
c release. Western blot analysis of mitochondrial extracts
derived from tumor livers of the different cohorts of mice
revealed a reduced mitochondrial level of Mcl-1 in NCD-fed IL-
6RaKO mice (Figure 2G). Interestingly, upon HFD feeding, mito-
chondrial Mcl-1 protein levels were restored to comparable
levels in both control and IL-6Ra-deficient animals (Figure 2G).IL-6RaKOmice fed on anNCD and sacrificed at the indicated time points after a
g concentrations of recombinant Bax. Mitochondria were isolated from naive
tracts from primary hepatocytes isolated from 8-wk control and IL-6RaKO mice
8-wk control and IL-6RaKO mice sacrificed at the indicated time points upon
on isolated mitochondria from DEN-injected 8-mo control and IL-6RaKO mice.
ol and IL-6RaKO mice. Dashed lines discriminate tumor and normal liver tissue.
ontrol and IL-6RaKO mice. 0 = no Mcl-1, 1 = low Mcl-1, 2 = high Mcl-1.
s from DEN-injected 8-mo control and IL-6RaKO mice.
control. See also Figure S2.
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Notably, protein levels of Bcl-2 and Bcl-XL were not altered
between diets and genotypes. Consistent with these data,
immunohistochemistry of mouse liver sections demonstrated
that HFD significantly increased Mcl-1 protein abundance in
the tumors independently of IL-6Ra signaling (Figures 2H
and 2I). The tumor-associated Mcl-1 expression was further
analyzed in dissected HCCs from livers of the different groups
of mice in western blot analysis, demonstrating that Mcl-1 pro-
tein was decreased in HCCs of lean IL-6Ra-deficient mice
compared to control tumors, while HFD increased Mcl-1 protein
in HCCs of control as well as IL-6RaKO mice (Figures 2J and
S2O). Strikingly, qPCR analyses of liver cDNA of the four dif-
ferent groups of mice revealed that the transcriptional level of
Mcl-1 was largely unaltered (Figure S2P), suggesting that the
reduced Mcl-1 content of mitochondria of IL-6RaKO mice might
be caused by a posttranslational regulatory mechanism. Taken
together, these experiments demonstrate that under NCD
conditions, loss of IL-6 signaling sensitizes hepatocytes to
damage-induced apoptosis. In turn, apoptosis may contribute
to the attrition of damaged cells with an enhanced malignant
potential and thus protects from tumor development. However,
under HFD conditions, hepatocyte apoptosis is inhibited, even
in the absence of IL-6Ra signaling, presumably by increased
protein abundance of the antiapoptotic Bcl-2 protein family
member Mcl-1, especially within the tumor lesions.
GSK-3b Inhibition Stabilizes Mcl-1 under Obese
Conditions in HCC Development
The Mcl-1 protein comprises an N-terminal PEST domain that is
responsible for its relatively short half-life. Among the numerous
protein kinases that have been implicated in the regulation of
Mcl-1, GSK-3b is known to play a pivotal role in controlling
Mcl-1 protein stability (Maurer et al., 2006). GSK-3b is a serine/
threonine protein kinase that unlike most other protein kinases
is constantly active, but becomes inactivated upon phosphoryla-
tion at serine residue 9 (S9). Interestingly, inactivation of GSK-3b
via phosphorylation at S9 increases stabilization and accumula-
tion of Mcl-1 protein and thus prevents apoptosis (Ding et al.,
2007). To address the role of GSK-3b action in Mcl-1 protein sta-
bility during HCC development, we analyzed GSK-3b phosphor-
ylation in the livers of DEN-treated control and IL-6RaKO mice on
either an NCD or HFD (Figures 3A and S3A). Remarkably, GSK-
3b was less phosphorylated at S9 and thus more active in livers
of IL-6RaKO mice on an NCD (Figures 3A, S3A, and S3B),
whereas total GSK-3b levels were unaltered (Figure S3C). Inter-
estingly, GSK-3b S9 phosphorylation was reconstituted and
Mcl-1 levels were increased in livers of IL-6RaKO mice when
exposed to HFD feeding (Figures 3A and S3A). Consistent with
these observations, direct assessment of GSK-3b kinase activity
showed that in livers of IL-6RaKO mice on an NCD, but not on
HFD, GSK-3b activity was significantly enhanced (Figure 3B).
Active GSK-3b has been previously demonstrated to regulate
apoptosis through expression of the BH3-only member PUMA
that antagonizes Mcl-1 to sensitize for apoptosis (Charvet
et al., 2011). Consistently, PUMA expression was 2-fold
increased in tumor livers of IL-6RaKO mice but restored under
obese conditions (Figure S3D). Of note, expression of the other
BH3 only family member NOXA was unchanged between geno-674 Cell Reports 4, 669–680, August 29, 2013 ª2013 The Authorstypes and diets (Figure S3E). We next examined whether inacti-
vation of GSK-3b is a downstream event of IL-6 signaling that in
turn stabilizes Mcl-1. Indeed, injection of IL-6 in control mice re-
sulted in marked phosphorylation of GSK-3b at S9 already
30 min postinjection, which was paralleled by increased Mcl-1
protein levels (Figure 3C). We then injected control and IL-
6RaKO animals with 100 mg/kg DEN and assessed Mcl-1 stabi-
lization and GSK-3b phosphorylation. While in control mice DEN
injection stabilizedMcl-1 over time as a consequence of GSK-3b
inactivation, this response was largely blunted in IL-6RaKO mice
(Figure 3D). Mcl-1 stabilization as well as GSK-3b phosphoryla-
tion in controls corresponded with circulating IL-6 that peaked
8 hr upon injection (Figure S3F), whereas Mcl-1 stability was
maintained up to 24 hr. However, PUMA peaked in both geno-
types 24 hr after DEN injection on both the protein and RNA level,
indicating that GSK-3b-independent mechanisms control PUMA
expression in these experiments (Figures 3D and S3G). Thus,
abrogation of IL-6 signaling results in decreased Mcl-1 protein
stabilization during the early phases of DEN-induced liver tumor-
igenesis. To directly address the role of GSK-3b regarding Mcl-1
stabilization in vivo, we injected control mice with adeno-associ-
ated viral vectors (AAV) expressing either GFP or a Myc-tagged
constitutive active GSK-3b variant (GSK-3bCA) harboring a
serine-to-alanine substitution at position 9 of GSK-3b (S9A) (Fig-
ure 3E). Western blot analysis using Mcl-1 antibody demon-
strated that expression of GSK-3bCA in livers of control mice
reduced Mcl-1 protein level after DEN injection (Figure 3E), simi-
larly to what was observed in IL-6RaKO animals (Figure 3D). In
line with our previous experiment, PUMA expression failed to
correlate with GSK-3b activity under acute DEN conditions,
although we observed increased PUMA protein in noninjected
GSK-3bCA-expressing livers (Figure 3E). These experiments
therefore reveal that GSK-3b inactivation by phosphorylation at
S9 is required during the initial phases of tumorigenesis to stabi-
lize Mcl-1 protein levels.
GSK-3b S9 phosphorylation mainly occurs through the action
of PI3K signaling (Cross et al., 1995). To determine the role of
PI3K signaling in DEN-induced HCC development of HFD-fed
mice, we treated HCC-bearing HFD fed control mice with the
specific PI3K inhibitor GDC-0941. Accordingly, administration
of GDC-0941 to tumor-bearing HFD fed mice resulted in reacti-
vation of GSK-3b (Figure 3F). Consequently, Mcl-1 protein levels
were reduced in the livers of thesemice when compared to HFD-
fed control mice, though livers of NCD fed IL-6RaKO mice still ex-
hibited lessMcl-1 protein (Figure 3F). Furthermore, the reduction
of Mcl-1 protein by inhibition of PI3K in tumor-bearing HFD fed
control mice resulted in an increase of TUNEL-positive cells, a
marker of apoptosis (Figures 3G and S3H). Moreover, Ki67 stain-
ing of tumor liver sections demonstrated that PI3K inhibition
reduced hepatocyte proliferation (Figures 3H and S3I). Impor-
tantly, the quantitative evaluation of apoptosis and hepatocyte
proliferation in livers of PI3K inhibitor-treated HFD fed control
mice revealed a significant increase in apoptosis and reduction
in proliferation comparable to that observed for NCD-fed IL-
6RaKO mice, which are protected against HCC development.
However, regardless of the result obtained from the pharmaco-
logical inhibition of PI3K, the formation of PIP3 was similar in
the cohorts of mice regardless of diet or genotype (Figure S3J).
Figure 3. GSK-3b Inhibition Stabilizes Mcl-1
under Obese Conditions in HCC Development
(A) Western blot analysis using pGSK-3b, GSK-3b,
Mcl-1, and AKT antibodies on liver tissue from DEN-
injected 8-mo control and IL-6RaKO mice.
(B) Determination of GSK-3b activity in liver lysates
from DEN-injected 8-mo control and IL-6RaKO mice
(n = 5).
(C) Western blot analysis using pGSK-3b, Mcl-1, and
AKT antibodies on liver tissue from 8-wk control
mice fed on NCD after intravenous (i.v.) injection of
50 ng IL-6.
(D) Western blot analysis using pGSK-3b, GSK-3b,
Mcl-1, PUMA, and Calnexin antibodies on liver tissue
from 8-wk male control and IL-6RaKO mice fed on an
NCD and sacrificed at the indicated time points after
injection of 100 mg/kg DEN.
(E) Western blot analysis using pGSK-3b, GSK-3b,
Mcl-1, PUMA, and Calnexin antibodies on liver tissue
from 8-wk control mice preinfected with AAV8 viruses
expressing GFP or GSK-3bCA at the indicated time
points after injection of 100 mg/kg DEN.
(F) Western blot analysis using pGSK-3b, Mcl-1 and
AKT antibodies on liver tissue from DEN-injected
8-mo control and IL-6RaKO mice treated with or without
GDC-0941.
(G) Quantitation of apoptotic cells in tumor liver
sections by TUNEL staining from DEN-injected 8-mo
control and IL-6RaKO mice treated with or without
GDC-0941 (n = 4).
(H) Quantitation of proliferating cells in tumor liver
sections by Ki67 staining from DEN-injected 8-mo
control and IL-6RaKO mice treated with or without
GDC-0941 (n = 4).
Displayed values are means ± SEM; *p % 0.05, **p %
0.01, ***p% 0.001 versus control. See also Figure S3.Even downstream AKT activity was unaltered in those groups of
mice as examined, on the one hand, by phosphorylation of AKT
at serine 473 (Figures S3K and S3L) as well as by the ability of
immunoprecipitated AKT to phosphorylate a GSK-3b S9
including peptide on the other (Figure S3M). Notably, these re-
sults are in discrepancy to the results obtained from whole-cell
lysates (Figures 3A, 3B, S3A, and S3B). Thus, PI3K/AKT
signaling is active, but not altered, in the absence of IL-6Ra
signaling in HCC development independent on dietary condition.
Obesity and IL-6-Controlled Expression of PP-1a and
Mule Synergize to Stabilize Mcl-1
Alteration of PI3K/AKT activity in lean IL-6Ra-deficient animals
failed to explain increased GSK-3b action, so we examined the
expression levels of protein phosphatase 1a (PP-1a), which cat-
alyzes the reverse reaction, namely GSK-3b dephosphorylation
at S9 (Figure 4A). Strikingly, expression levels of PP-1a were
more than 2-fold increased in IL-6Ra-deficient mice in the
DEN-induced HCC protocol when compared to controls (Fig-Cell Reports 4, 669ure 4A). Transcriptional control of IL-6-regu-
lated gene expression is mainly mediated
through the transcription factor Stat-3, whose
activation was reduced in lean IL-6RaKO mice
in acute as well as chronic DEN experiments(Figures S4A and S4B). Evidently, both the restored hepatic
Stat-3 activation in obese IL-6RaKO mice and the remaining
DEN-induced Stat-3 activation in lean IL-6RaKOmice occur inde-
pendently of IL-6, thus indicating another obesity- and/or DEN-
induced factor that activates Stat-3 in the absence of IL-6Ra
(Figures S4A and S4B). Careful investigation of the PP-1a pro-
moter revealed a conserved Stat-3 binding site between mice
and humans upstream of transcriptional initiation (Figure S4C).
To address whether this motif is bound by phosphorylated
Stat-3 in response to IL-6, we performed chromatin immunopre-
cipitation (ChIP) experiments of basal and IL-6-stimulated
HepG2 cells that demonstrated activated Stat-3 at this site under
basal conditions but IL-6 stimulation increased the presence of
Stat-3 at this motif (Figure 4B). To determine whether PP-1a is
a direct IL-6 target in vivo and how expression is affected by
IL-6-induced Stat-3 activation, we injected a cohort of C57/
BL6 mice with IL-6 and examined relative hepatic expression
of PP-1a in a time frame until 240 min after IL-6 injection (Fig-
ure 4C). PP-1a expression was significantly reduced upon IL-6–680, August 29, 2013 ª2013 The Authors 675
Figure 4. Obesity and IL-6-Controlled Expression of PP-1a and Mule Expression Synergize to Stabilize Mcl-1
(A) qPCR of PP-1CA in liver of DEN-injected 8-mo male control and IL-6RaKO mice fed on either NCD or HFD (n = 6).
(B) ChIP using RNA polymerase II, immunoglobulin G, and pStat-3 antibodies on sonicated DNA isolated from HepG2 cells stimulated with 200 ng/ml IL-6 for
45 min using oligos 5hPP1CAChip and 3hPP1CAChip to examine the PP-1CA promoter.
(C) qPCR of PP-1CA in liver of 8-wk control mice fed on NCD after i.v. injection of 50 ng IL-6 (n = 5).
(D) qPCR of Mule, FBW7, and Cul1 in liver of DEN-injected 8-mo male control and IL-6RaKO mice (n = 6).
(E) ChIP using RNA polymerase II, immunoglobulin G, and pStat3 antibodies on sonicated DNA isolated from HepG2 cells stimulated with 200 ng/ml IL-6 for
45 min using oligos 5hMULEChip and 3hMULEChip to examine Mule promoter.
(F) Luciferase activity of lysates obtained from HepG2 cells transfected with pTEMule-Luc and pRL null stimulated with IL-6 and/or preincubated with 20mM
STATTIC (n = 9/stimulation).
(G) qPCR of Mule in livers of 8-wk control and constitutive active Stat-3L-C mice (n = 4).
(legend continued on next page)
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treatment 60 min postinjection and progressively declined up to
240 min, indicating that PP-1a is a transcriptional target for IL-6-
induced repression (Figure 4C). Noteworthy, IL-6-induced AKT
activation already declined 60 min after injection (Figure S4D).
To examine whether PP-1a inhibition is sufficient to stabilize
Mcl-1 protein in acute DEN injection experiments in vivo, we
applied the specific PP-1a inhibitor okadaic acid (OA) 1 hr before
DEN injection in lean control and in IL-6Ra-deficient animals and
investigated the S9 phosphorylation of GSK-3b as well as Mcl-1
protein abundance (Figure S4E). Expectedly, PP-1a inhibition re-
sulted in the persistent phosphorylation of GSK-3b in both IL-
6Ra-deficient and control mice (Figure S4E). However, hepatic
Mcl-1 protein levels in IL-6Ra-deficient mice were still reduced
when PP-1a was inhibited, hinting to another synergistic
pathway independent of PP-1a and GSK-3b that destabilizes
Mcl-1 in lean IL-6Ra-deficient mice. Of note, OA treatment in
mice with liver-specific GSK-3bCA expression also reduced
Mcl-1 protein levels (Figure S4F).
Recently, GSK-3b-phosphorylated Mcl-1 has been shown to
be recognized by either Mule or the SCFFBW7 E3 ligase, both of
which ligate polyubiquitin chains to Mcl-1 that lead to its protea-
somal degradation (Wertz et al., 2011; Zhong et al., 2005). In
order to determine whether the expression of these E3 ligases
correlate with Mcl-1 levels in lean and obese control and IL-
6Ra-deficientmice, we performed qPCR analyses of tumor livers
from these mice (Figure 4D). Strikingly, while we observed a
2-fold elevated expression of Mule in lean IL-6Ra-deficient
mice compared to lean controls, Mule expression was signifi-
cantly reduced under obese conditions in mice of both geno-
types (Figure 4D). Interestingly, comparing the expression levels
of the subunits FBW7 and cullin 1 of the SCFFBW7 complex to
Mule expression revealed a 20-fold lower FBW7 expression
and 5-fold lower cullin 1 expression, indicating that Mule rather
than the SCFFBW7 E3 ligase complex might play a role in liver
carcinogenesis by interfering with Mcl-1 protein stability (Fig-
ure 4D). This result yielded the assumption thatMule expression
is directly inhibited by IL-6 and that impaired suppression of
Mule in IL-6Ra-deficient mice during HCC initiation and progres-
sion might result in increased Mcl-1 protein turnover and
apoptosis. Consistently, examination of Mule expression in
acute DEN injection experiments revealed that IL-6Ra-deficient
mice showed an impaired suppression of Mule in response to
DEN when compared to controls (Figure S4G). In line with these
experiments that face to an important role of IL-6-induced Stat-3
in the inhibition of Mule expression, we analyzed the promoter
region of Mule and identified two conserved Stat-3 binding
motifs between mice and humans within a region upstream of
Mule transcriptional initiation (Figure S4H). Chip experiments of
basal and IL-6-stimulated HepG2 cells revealed active Stat-3
bound to the Mule promoter at the basal state, whereas IL-6
stimulation increased Stat-3 binding to these sites (Figure 4E).
Of note, binding of activated Stat-3 to the Stat-3 motifs in the(H) Western blot analysis using pStat-3, Mcl-1, AKT, Mule, pGSK-3b, and Calnex
stimulated with 50 ng/ml IL-6 for the indicated time points.
(I) Mcl-1 and Mule stainings of five different human HCC sections.
Displayed values are means ± SEM; *p% 0.05, **p% 0.01, ***p% 0.001 versusMule promoter was specific, as using oligos more distal to these
sites revealed still actively bound RNA polymerase II but not
active Stat-3 (Figure S4I). To directly clarify whether Mule
expression is subjected to IL-6-induced repression, we cloned
1,000 bp upstream of Mule exon 1 that contains the promoter
including regulatory elements in front of a firefly luciferase and
transfected this construct into HepG2 cells (Figure 4F). Examina-
tion of luciferase activity revealed significantly 40% reduced
Mule promoter activity upon IL-6 stimulation, whereas luciferase
activity substantially increased when transfected cells were
incubated in the presence of the Stat-3 inhibitor STATTIC (Fig-
ure 4F). Accordingly, investigation of mice expressing a constitu-
tive active Stat-3 variant in hepatocytes revealed a 40% reduced
Mule expression similar to our in vitro findings (Figure 4G). There-
fore, our analyses reveal that expression of the ubiquitin ligase
Mule is directly regulated by IL-6- and obesity-controlled
Stat-3 activation that impacts on Mcl-1 stability and thus alters
apoptosis sensitivity.
In order to verify our mechanism of Mcl-1 stabilization in vitro,
we stimulated primary hepatocytes derived from control and IL-
6Ra-deficient animals with 50 ng/ml IL-6 in a time frame and per-
formed western blot analysis (Figure 4H). This analysis revealed
that IL-6 treatment increased Mcl-1 protein, inhibited GSK-3b
activity, and repressed Mule expression in control hepatocytes,
whereas these processes were not present in IL-6Ra-deficient
cells (Figure 4H). Notably, these experiments also demonstrate
that our mechanism of IL-6-induced Mcl-1 stabilization is more
pronounced in vivo that might point to an auxiliary function for
IL-6 in liver nonparenchymal cells. IL-6 signaling in these cells
might in turn promote hepatic Mcl-1 stabilization through other
indirect means. Nevertheless, we verified our in vivo mechanism
of IL-6-induced Mcl-1 stabilization in primary hepatocytes,
although IL-6 action in vivo is more effective to stabilize Mcl-1.
IncreasedMcl-1 levels have previously been reported in a sub-
set of human HCC (Fleischer et al., 2006); however, the correla-
tion betweenMcl-1 andMule has never been addressed in HCC.
Therefore, we examined human HCC samples in immunohisto-
chemistry using anti-Mule and anti-Mcl-1 antibodies, revealing
that Mcl-1 expression in human HCC negatively correlated
with Mule expression (Figure 4I). We classified cases that
showed no steatosis (#1 and #2), steatosis (#3), and a steatohe-
patitic pattern (#4 and #5) by visible lipid inclusions into the liver.
While, the nonsteatotic cases #1 and #2 showed almost noMcl-1
expression and high Mule expression, the steatohepatitic HCC
cases #4 and #5 exhibited the most prominentMcl-1 expression
accompanied with a reduction in Mule expression, implicating
our experiments as truly translational and ominous in light of
the steadily increasing obesity epidemic. Collectively, our exper-
iments demonstrate that obesity and IL-6 signaling synergize to
affect the protein stability of the Bcl-2 family member Mcl-1 via
GSK-3b inhibition and repression of Mule expression to inhibit
the mitochondrial apoptotic pathway during HCC development.in antibodies of primary hepatocytes derived from control and IL-6RaKO mice
control. See also Figure S4.
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DISCUSSION
The current obesity epidemic in westernized societies repre-
sents a major health burden owing to the development of
obesity-associated diseases. The excessive weight gain in
obesity is accompanied with a chronic inflammatory state mainly
derived from obese WAT that releases TNF-a and IL-6 into the
bloodstream (Xu et al., 2003). Interestingly, epidemiological
studies identified HCC as a cancer entity, the risk of which is
clearly increased in obese subjects, particularly in men with a
body mass index of more than 35 (Calle et al., 2003). However,
the impact of obesity-induced low-grade inflammation on the
development of neoplastic lesions has not yet been studied in
detail.
Importantly, the enhanced development and progression of
HCC in obesity can be recapitulated in mouse models for HCC
to elucidate the underlying molecular mechanisms of obesity-
induced HCC development (Park et al., 2010; Wunderlich
et al., 2008). Recently, Park et al. (2010) demonstrated that
both dietary- and genetically induced obesity in mice increase
HCC development as a consequence of obesity-induced eleva-
tion of both TNF-a and IL-6. In this context, increased IL-6 levels
in obesity were predicted to inhibit hepatocyte apoptosis, a
driving force in DEN-induced HCC development. Our study
has now identified that stabilization of Mcl-1 is the molecular
basis for IL-6-induced protection from apoptosis in lean mice.
Along this line, previous studies have clearly demonstrated that
Mcl-1 is an antiapoptotic factor for a subset of human HCC,
whose inhibition might have potential in human therapy
(Fleischer et al., 2006; Schulze-Bergkamen et al., 2006), but
may also result in liver damage and cancer development (Vick
et al., 2009; Weber et al., 2010). It has been previously demon-
strated that hepatocyte-specific Mcl-1 inactivation causes
spontaneous HCC in old mice as a consequence of a microenvi-
ronment comprising apoptosis-sensitive Mcl-1-deficient hepa-
tocytes and compensating adjacent hepatocytes (Weber et al.,
2010). Of note, HCC development in these mice occurs in the
absence of chronic inflammation. Interestingly, the compound
inactivation of Mcl-1 and BAK not only normalizes apoptosis
sensitivity of hepatocytes but also prevents liver cancer develop-
ment (Hikita et al., 2012). However, the Mcl-1-deficient mouse
model of liver cancer is different from our DEN-induced HCC
model, which depends on high Mcl-1 levels that are translatable
to human disease (Fleischer et al., 2006) and where IL-6 action
stabilizes Mcl-1 protein through inhibition of posttranslational
mechanisms. Of note is that unlike other Bcl-2 family members,
Mcl-1 has a dynamic turnover rate (Kozopas et al., 1993; Maurer
et al., 2006). While Mcl-1 expression at the transcriptional level
depends on PI3K-mediated signal transduction as well as IL-6-
evoked signaling (Epling-Burnette et al., 2001; Jourdan et al.,
2003; Wang et al., 1999), the dynamic turnover rate of Mcl-1 is
controlled by GSK-3b phosphorylation leading to its polyubiqui-
tylation and subsequent proteasome-mediated degradation
(Maurer et al., 2006). The regulation of GSK-3b is complex and
controlled at multiple levels and its misregulation is known to
contribute to the development of numerous diseases such as
diabetes, Alzheimer disease, and cancer (Eldar-Finkelman and
Krebs, 1997; Eldar-Finkelman et al., 1999; Hanger et al., 1992;678 Cell Reports 4, 669–680, August 29, 2013 ª2013 The AuthorsPatel and Woodgett, 2008). While S9 in GSK-3b is mainly a sub-
strate for AKT phosphorylation in response to insulin (Cross
et al., 1995), phosphorylation of this site can also be catalyzed
by PKA or PKC (Fang et al., 2000, 2002;Wang et al., 1994).What-
ever the nature of the upstream kinase that controls GSK-3b
phosphorylation, our experiments reveal that its activity in HCC
is controlled via both the activation of PI3K signaling and
PP-1a that catalyzes the removal of S9 phosphorylation. While
we clearly demonstrate that PI3K/AKT action is not impaired in
the absence of IL-6Ra signaling, our experiments reveal a critical
role of IL-6 signaling in the control of PP-1a expression.
However, while S9 phosphorylation-dependent control of
GSK-3b kinase activity was shown to regulate Mcl-1 protein
stability, GSK-3b action requires prephosphorylation of Mcl-1
in order to exert its regulatory function (Maurer et al., 2006; Morel
et al., 2009). Nevertheless, we found in our mouse model that
GSK-3b phosphorylation correlated with Mcl-1 protein stability.
However, at this point we cannot rule out that depending on
dietary conditions IL-6Ra signaling in addition to GSK-3b regula-
tion also controls the activity of additional Mcl-1 kinases. In line
with this notion, previous studies have suggested that MAPK/
ERK and JNK-dependent phosphorylation of Mcl-1 may also
decrease Mcl-1 stability (Domina et al., 2004; Kodama et al.,
2009; Morel et al., 2009). Further, increased and sustained
JNK-1 activity, as observed in obesity (Hirosumi et al., 2002)
and during DEN-induced HCC development (Hui et al., 2008),
can stabilize Mcl-1 (Kodama et al., 2009).
The protein stability ofMcl-1 critically depends on the action of
E3 ubiquitin ligases that polyubiquitylate Mcl-1 leading to its pro-
teosomal degradation. In particular, the SCFFBW7 complex and
Mule have been described in this context (Wertz et al., 2011;
Zhong et al., 2005). While we detected only marginal expression
of the subunits FBW7 and cullin-1 in HCC, we demonstrate that
Mule expression is a direct target of IL-6-mediated Stat-3
repression and that in human HCC, Mcl-1 levels negatively
correlate withMule expression. Thus, in leanmice, IL-6 exagger-
ates Mcl-1 stabilization in HCC by controlling the synergistic
actions of GSK-3b and Mule. In contrast, in obesity, DEN-
induced HCC development and progression occurred even
in the absence of IL-6Ra expression as a consequence of
obesity-induced GSK-3b inhibition and transcriptional repres-
sion of Mule leading to Mcl-1 stabilization. Along these lines,
inhibitory S9 phosphorylation of GSK-3b was increased upon
HFD feeding both in control and IL-6RaKO mice, whereas Mule
expression was significantly inhibited under obese conditions
not only in control but also in IL-6Ra-deficient animals. Therefore
in lean mice, IL-6 appears to be the critical regulator of GSK-3b
as well as Mule inhibition, while alternative signals may control
thesemolecules in obesemice. Interestingly, while the increased
tumor burden in obese mice was accompanied with increased
Mcl-1 levels in tumor lesions independently of IL-6Ra signaling,
the severity of tumor-specific lipid accumulation in human HCC
positively correlated with Mcl-1 abundance. Apparently, our ex-
periments refer to a not-yet-identified factor that compensates
for IL-6Ra deficiency in obesity-associated HCC development.
We have good indication that another IL-6-type cytokine or re-
ceptor might represent this obesity-induced factor as inactiva-
tion of gp130 in hepatocytes protects against DEN-induced
HCC development even under obese conditions. We propose
that this factor is increased also in the proinflammatory state in
obesity, thereby elevating basal hepatic Stat-3 activation but
impairing acute factor-induced responsiveness. Indeed, we
have demonstrated such characteristics for IL-6 under obese
conditions. While the identification of the obesity-induced factor
that stabilizes Mcl-1 might open novel avenues to treat human
HCC, it would clarify another interesting aspect of our study,
namely the apparent differential effect of predescribed IL-6 defi-
ciency versus our results on IL-6Ra deficiency in obesity-
induced HCC development. Both IL-6 and IL-6Ra deficiency in
lean mice protect against HCC development, whereas in the
obese state, IL-6RaKO mice exhibit similar tumor numbers as
control mice but IL-6 knockout mice fail to develop HCC under
these conditions (Park et al., 2010). In line with these reported
differential effects, a recent publication demonstrated a similarly
different experimental outcome in IL-6- and IL-6Ra-deficient
mice when addressing the function of IL-6 in wound healing
(McFarland-Mancini et al., 2010). While IL-6-deficient mice
demonstrated a greatly reduced wound-healing capacity, IL-
6Ra deficiency showed only slightly impaired wound healing.
Further analysis of double-knockout mice revealed that IL-6Ra
deficiency dominated wound-healing capacity. Thus, these
studies and our latest findings point toward a more complex
role of IL-6Ra signaling in inflammatory processes than hitherto
assumed. Collectively, our study has clearly identified IL-6- and
obesity-induced Mcl-1 stabilization as a critical factor for HCC
development and progression. Moreover, our study provides
evidence that under obese conditions, IL-6Ra-dependent regu-
lation of GSK-3b andMule is compensated for by an alternative
mechanism. Thus, this study has strong implications for current
translational research on HCC and the development of novel
therapeutic strategies aiming at reactivating the mitochondrial
apoptotic pathway under inflammatory and obese conditions.
EXPERIMENTAL PROCEDURES
Care of all animals was within institutional animal care committee guidelines
and all animal procedures were approved by local government authorities
(Bezirksregierung Ko¨ln, Cologne, Germany) and were in accordance with
NIH guidelines. Experimental procedures are described in detail in the
Extended Experimental Procedures.
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